Vaxart, Inc. (VXRT) Earnings Call Transcript & Summary

November 13, 2024

OTC Pink Market US Health Care Biotechnology earnings 34 min

Earnings Call Speaker Segments

Ed Berg

executive
#1

Hello, everybody, and thank you for being on the call today. Steven Lo, our Chief Executive Officer, is here representing Vaxart, along with Dr. Sean Tucker, who founded the company and serves as Chief Scientific Officer; Dr. James Cummings, our Chief Medical Officer; and Phil Lee, our Chief Financial Officer. Ahead of beginning, please be aware that during this conference call, Vaxart may issue forward-looking statements. Among these are statements concerning the company's financial results, financial guidance, future business strategies and operations, and product development and regulatory progress, including statements about clinical trials that are ongoing or planned. The outcomes we ultimately achieve may vary significantly from what these forward-looking statements suggest, given several key considerations — among them the unpredictability that naturally accompanies clinical development and the regulatory review process, plus additional risks outlined under the Risk Factors heading in Vaxart's latest annual report on Form 10-K, as well as in other periodic filings made with the SEC. Vaxart assumes no duty to revise any forward-looking statements once this call has taken place. At this point I'll hand things over to Steven Lo. Steve?

Steve Lo

executive
#2

Thank you, Ed, and I appreciate everyone taking the time to be with us this afternoon. During this call, I'm eager to walk through several achievements we've made since we last provided an update. After that, James and Sean will each give updates on our COVID, norovirus and HPV programs prospectively. Phil will then go over our financial results, and following that we'll take your questions. When I came on board at Vaxart earlier this year, we established clear objectives aimed at moving our oral pill vaccine platform forward and delivering a potentially transformative solution to improve public health. Our platform not only shows promise in tackling many weaknesses of injectable vaccines — for instance, harnessing mucosal immunity to potentially prevent infection and transmission — but it also offers greater convenience in delivery and has shown a favorable safety and tolerability profile across 19 clinical trials to date. All told, we continue to see the possibility of a genuinely differentiated and transformational platform. Today, I'm happy to share that we've reached several milestones in carrying out our goals. Beginning with our COVID program, through our partnership with BARDA, we've made a major advance in discovering a new approach to fighting pandemics going forward. In September, we began enrollment in our Phase IIb study testing our COVID-19 oral pill vaccine candidate against an approved mRNA vaccine comparator. Interest in our trial is strong, and our goal is to move this study forward as rapidly as we can. James will go into this trial in more detail shortly, but I want to point out that as recipients of one of the largest BARDA-funded project Next-Gen awards to date, now valued at up to $456 million, we appreciate this collaboration and look forward to continuing our work with our government partners. As we monitor vaccination trends this season, we've observed COVID vaccinations rising substantially after KP.2 availability starting in late August and early September. In fact, data tracked by IQVIA indicates that roughly 35 million people will get a COVID vaccine dose in the U.S. alone. That's comparable to last year's season of approximately 40 million doses. Given these trends, it's clear there's still robust demand for a COVID vaccine, and we believe our solution can meet this demand more efficiently and effectively than current injectable methods. Moving to our norovirus program. We've had productive communication with FDA and recently received constructive feedback on our data for potential correlates of protection. Sean will provide a deeper dive into our assessment and planning, but I'll note that we're taking a thoughtful approach to the best way to advance this program. We're meeting with a number of advisers and disease experts as we assess the best clinical development path. Beyond the discussions we've had with the FDA, it was a pleasure to share encouraging results from our studies at Infectious Disease Week and the World Vaccine Congress, which highlights how dedicated we are to addressing this major unmet need, since no vaccines have been approved to date for norovirus. This virus spreads very easily and ranks as the top cause of acute gastroenteritis symptoms including vomiting and diarrhea, making about 21 million individuals in the United States ill annually. Among our 3 pipeline programs, this one targets a multibillion dollar market, and we are committed to moving it ahead. Alongside our 2 lead clinical programs in COVID and norovirus, we keep seeking chances to push our remaining programs forward through prudent investment, so as to advance additional indications. For instance, we just published pharmacy preclinical data regarding our HPV vaccine constructs in the August issue of vaccines, indicating that our mucosal vaccine platform could offer a noninvasive way to stop progression to cervical cancer. Further preclinical work is scheduled to better define the immune stimulating and antitumor activity of our HPV vaccine. We are eager to provide updates from our BARDA-funded Phase IIb COVID trial, outline the next steps for our norovirus program, and identify the strongest strategic opportunities for our other programs. I'll now hand the call over to James for a deeper review of recent progress on our COVID-19 program.

James Cummings

executive
#3

Appreciate that, Steve. An important readout is going to come from the BARDA Phase IIb clinical trial, and it could give further validation for our platform while underscoring that a new option might exist as an alternative to the injected COVID-19 vaccines currently available. Our view is that cross reactivity among our vaccine candidates, along with mucosal immune responses, might deliver a meaningful effect against variants as they evolve, and do so with safety and tolerability that looks better than the mRNA comparator. Drawing on data from earlier trials, our vaccine candidates demonstrated that study participants developed higher IgA antibodies against SARS-CoV-2 — the virus responsible for COVID-19 — all while keeping immunization protection going against COVID-19 variants now and in the future, plus a tolerability profile that was benign; our thanks go to BARDA for strong leadership, partnership and funding that turned this Phase IIb trial into something real. Keep in mind that this Phase IIb clinical trial is double-blinded, multicenter, randomized and comparator-controlled, designed to establish relative efficacy, safety and immunogenicity for Vaxart's oral pill COVID-19 vaccine candidate versus an approved mRNA COVID-19 injectable vaccine among adults who had already been immunized against COVID-19 infection. A sentinel cohort of 400 participants is involved, with 200 getting Vaxart's XBB vaccine and 200 getting an approved mRNA XBB vaccine comparator. Enrollment of these participants is going well, and we expect dosing for the cohort to wrap up later this month. After enrollment finishes, the 30-day safety data covering the initial 400 participants will be reviewed by an independent Data Safety Monitoring Board, or DSMB, together with the U.S. FDA. If the reviewers give a signal to proceed, the remaining 10,000 participants will then be enrolled for the second phase of this study. Efficacy for symptomatic and asymptomatic disease, systemic and mucosal immune induction, and safety are what the Phase IIb study will measure. Relative efficacy of Vaxart's COVID-19 vaccine candidate against an approved mRNA COVID-19 vaccine for preventing symptomatic disease serves as the primary endpoint. The primary efficacy analysis happens once every participant has either discontinued or completed a study visit 12 months post vaccination; enrolling this study fully should take roughly 6 months, based on our expectations. Now I'll pass the call to Dr. Sean Tucker, our Founder and Chief Science Officer, who will briefly discuss our norovirus program and our recent HPV publication. Sean?

Sean Tucker

executive
#4

Thank you, James. As Steve said before, we got helpful input from the FDA regarding our data on a possible correlate of protection and the subsequent steps for our norovirus program. Although we think we've pinpointed a functional antibody response that could be linked to protection against norovirus, the FDA asked for additional clinical data prior to moving ahead with any further review of our potential correlate; we're going over the FDA's current guidance and speaking with disease experts prior to revealing what comes next for our program. In addition, we've developed extra norovirus GI.1 and GII.4 constructs that, in our view based on preclinical data, might be more potent than the constructs currently under evaluation in clinical trials. We're talking over the FDA's regulatory feedback, the clinical data on the existing constructs, and the preclinical data from our new constructs with our advisers and some key opinion leaders to help us figure out the optimal path forward for our norovirus program; we're eager to move the norovirus program ahead using the best information and technology available, as part of our dedication to creating the first approved oral norovirus vaccine. Last month, I was honored to present data tied to our norovirus <<inaudible>> study at IDWeek. I'd like to use this moment to share several key points from my presentation; it highlighted promising results from our Phase II double-blinded, placebo-controlled study assessing our GI.1 vaccine candidate versus placebo administered to healthy subjects infected 29 days plus after vaccination. Our oral norovirus vaccination was demonstrated to bring about mucosal and systemic immune responses, with our strongest effects against infection and shedding when faced with a rigorous human viral challenge model. Using machine learning, we can pinpoint possible immune correlates of protection, protection against infection, most closely tied to generating a functional antibody response to norovirus and fecal IgA. By comparing how well a variety of individual markers predict and ranking them, we'll determine if merging individual immune markers enhanced prediction of protection against norovirus. Also, I'm happy to share the results from our colleague, Dr. Lam, wins presentation at IDWeek concerning our Phase I study of value our norovirus vaccine candidate in healthy lactating females and their nursing infants. Our candidate's safety profile matched our earlier trials, with a side effect profile comparable to placebo, and it was well tolerated in the post part of lactating subjects. Regarding immunogenicity, antibodies to norovirus increased on average fourfold for the GI.1 virus stream and sixfold for the GII.4 virus strain in the breast milk of lactating mothers who got the Vaxart vaccine candidate in the high dose group. Moreover, we discovered those antibodies could be tacted in fecal samples from breast feeding infants, indicating the possibility of passive transfer via breast milk; we're still investigating the durability of the immune response, nasal and soluble IgA responses, and safety through 365 days. Considering how hard it is to create a norovirus vaccine for infants, these results in breastfed babies mark a significant and inventive first move toward a norovirus vaccine that is safe and immunogenic, with the potential to reduce how severe norovirus is in infants. On the whole, we feel great motivation and commitment to keep advancing our oral pill norovirus vaccine program, which has shown strong immunogenicity, encouraging efficacy, and a favorable safety and tolerability profile so far. All of this evidence together will help shape our clinical development plan. Turning to our HPV program, I'm happy to report that we recently published encouraging preclinical findings on our HPV vaccine constructs in the August edition of Vaccines. What we found preclinically was that Vaxart's HPV vaccine constructs trigger specific T cell immune responses in an animal model of HPV-related tumor agenesis; those findings also hinted that giving a mucosal vaccine against these proteins to mice bearing HPV-expressing tumors resulted in smaller tumors and better survival. Such findings back the potential of our mucosal vaccine platform as a conceivable noninvasive way to stop progression to cervical cancer. We have more preclinical work scheduled to better define the immune stimulating and antitumor activity of our HPV vaccine. At this point I'll pass the call to Phil Lee, our CFO, who will give a short discussion of our financials. Phil?

Phil Eric Lee

executive
#5

Thanks, Sean. Today's press release contains a summary of the specifics behind our financial results for Q3 of 2024. For the third quarter of 2024, revenue came in at $4.9 million, which compares with $2.1 million during the same quarter in 2023. Most of that Q3 2024 revenue came from government contracts tied to BARDA. During Q3 of 2023, most revenue came from amounts recognized for work done under Vaxart scrap from the Bill & Melinda Gates Foundation, plus noncash royalty revenue generated by Inavir sales in Japan. As of the close of Q3 2024, Vaxart held cash, cash equivalents and investments totaling $58.7 million. Under our present plan, Vaxart still expects its cash runway to extend into 2026. Thanks to all of you for spending time with us today. At this point, we'll open up the call so you can ask questions.

Cheng Li

analyst
#6

Cheng here, calling in from Oppenheimer. We've got a few questions for you. To start, regarding that COVID-19 Phase II trial — I'd like to hear your thoughts on how interested the investigators seem, and how enrollment is trending compared to whatever targets you've set internally. Also, I recall you previously mentioned a possible interim look at the Phase IIb data, so is that still the plan, triggered once a specific number of events have accumulated? Then my second question concerns the norovirus program. Could you give us additional detail about the feedback the FDA provided? In particular, what new clinical data are they asking for?

Steve Lo

executive
#7

Thanks, and I appreciate the questions. This is Steve. I'll take the first one, then hand things to Sean for the remaining 2. On investigator interest and enrollment — as we mentioned during the opening remarks, we're quite pleased to remain on track toward reaching 400 participants in the sentinel study. Enrolling patients hasn't posed any difficulties for us. There is definitely interest. Based on what we're seeing with vaccines currently on the market, uptake of the COVID shot remains fairly strong. So from where we sit, things are progressing nicely, and we expect to share an update soon. Once we hit that 400, I'll pass it to Sean regarding the interim analysis.

Sean Tucker

executive
#8

Yeah. Regarding what you asked about the interim analysis alongside our BARDA partners, we're looking at an interim analysis that would assess both safety and efficacy signals. That said, what we're focused on and committed to is finishing the entire study all the way through the 12 months visit after vaccination for every participant who completes the trial. Early data out of our earlier clinical and preclinical work shows our vaccine brings about a mucosal immune response that could prove better than injectables, and that's a thing we are — we'll be digging into over the course of the trial.

Steve Lo

executive
#9

Then, regarding the last question, it concerned particular feedback coming from the FDA about norovirus? Cheng, I simply want to confirm that we have your final question right.

Cheng Li

analyst
#10

Yeah, I'd like to hear whatever particular feedback you're able to pass along regarding the conversation with the FDA, and also, what specific clinical data is needed for the next step?

Sean Tucker

executive
#11

Sure. So clearly, we've had those discussions with the FDA. Getting into a Phase IIb study at an end of Phase II meeting is what we're aiming for. We did receive some clarity regarding what the requirements are going to be. We won't go into the details right now, but we believe we came away with a clearer path forward toward success and toward getting it in the Phase II meeting.

Mayank Mamtani

analyst
#12

Great work on the advancement. It appears enrollment for the COVID sentimental group moved along quite rapidly. I'd really like to hear what you think regarding the DSMB 30-day safety analysis. What exactly are you looking for there, or what is the assembly and FDA seeking on their end? Also, how are you handling the study blind at this point? And regarding the mucosal immunity related endpoints you're evaluating, is there anything you could say about what to expect for potential separation versus the mRNA vaccine? It looks like your clinical trials gov page lists quite a few serum, nasal, and T-cell endpoints. Could you give any color there? And then I have a quick follow-up about norovirus.

Sean Tucker

executive
#13

Sure. Regarding the first question, when you ask about the DSMB feedback and what we expect, well, we remain blinded. So the DSMB will compile a summary, and our expectation is that no safety concerns will arise, and we'll keep enrolling once it's done. That's what we'd expect. And what — and your second question again, Mayank, just — oh, it concerned the samples. Yes, we're collecting saliva, nasal, swabs and clearly, some PBMCs from the standpoint of the 10,000 subjects, and we'll obtain some analysis regarding how each vaccine will perform or regarding generating those mucosal as well as systemic responses. Again, we're still blinded, so we won't see that data for a while, but the goal is to definitely compare the 2 vaccines for systemic and mucosal immune induction.

Mayank Mamtani

analyst
#14

Got it. And perhaps just to clear things up regarding that interim analysis you're planning — you definitely want it at the 12-month mark, and it might involve fewer than 10,000 participants. Did I understand correctly that this is something you'd be open to considering?

Sean Tucker

executive
#15

That's right. What the protocol currently specifies is that an interim analysis was scheduled to take place after 225 cases occurred — actually 255, my apologies, someone just set me straight on that. At that stage, an interim analysis would be conducted to examine how the 2 vaccines differ. Once more, this concerns relative efficacy, so basically the question being asked is how many individuals within each arm had contracted SARS-CoV-2. That forms part of — once more, as part of the protocol as it stands today. Once more, we remain in talks with our partners regarding what they plan to do. And — yet what matters most from where we sit is that we'd like to examine 12 months of data when this concludes, since I think that will prove highly informative, especially given that new variants will emerge across that 12-month stretch.

Mayank Mamtani

analyst
#16

That's quite useful. Then, regarding the next-gen norovirus GI.1 and GII.4 constructs. Sean, is there anything you can say about how the construct is designed, and whether you plan to publish preclinical data you've likely been gathering by now? And as much as you're able, could you lay out the picture on the correlates you're working on with the FDA, and how what's learned there might help speed up these next-generation candidates?

Sean Tucker

executive
#17

Yes. That's a really good question. So some of that data in mice we have shared. What we've observed is that both the GI.1 and GII.4, which we refer to as next-generation constructs, appear to be far more potent when it comes to eliciting antibody responses against either GI.1 or GII.4. The main point, I think, is that what we've discovered, and have provided across our platform, is that small modifications to how the backbone is set up, along with some of the structures, have led us to see meaningful gains in immunogenicity in preclinical models. Naturally, at some stage we intend to test these things in the clinic. You also asked about the correlates; and yes, a couple of things have been identified by us that matter greatly when it comes to predicting protection from norovirus following the GI.1 challenge; and those learnings can make it much simpler to apply toward your process optimization or clinical development, since knowing what to look for makes reaching the finish line much easier. And potentially, when you examine the new constructs, you can tell whether you're going to meaningfully boost the efficacy for the study. So yes, everything we've learned in the original GI.1 challenge, plus the things we've been discussing with the FDA, can be applied to either new or next-generation constructs.

Mayank Mamtani

analyst
#18

On the IND side, did you mention when these constructs would be ready? I realize manufacturing tends to move fast for your team, but are you giving any guidance on an IND filing timeline?

Sean Tucker

executive
#19

Correct. No guidance has been offered by us so far. And as matters progress — as we keep advancing our constructs — we'll make people aware.

Liang Cheng

analyst
#20

This is Liang Cheng, on behalf of Roger from Jefferies. My first question concerns the COVID program. I'm curious whether you anticipate any effect on enrollment, given the seasonality of COVID? Also, do you believe there would be any effect on the infection rate, considering it's now in number, and you were considering 6 months of enrollment — 6 months to complete enrollment?

Steve Lo

executive
#21

Yes, Liang, thank you for the question; regarding enrollment, what I can share is that, as things stand, we have not observed any enrollment issues with the sentinel cohort relative to our projections, and we collaborate very closely with the study sites and our CRO. No feedback has come back indicating that we ought to be broadly worried about enrollment. So as far as we're concerned, it's all systems go. I'll hand it over to Sean for his comments.

Sean Tucker

executive
#22

Yeah. I suppose your question was about how often people get infected and the emergence of new variants. Clearly, that's a crucial factor with any COVID vaccine effort, since the viral lineages in circulation shift pretty quickly, and within 3 or 4 months, additional strains will appear. As I understand it, KP.3 is currently the dominant one going around, though that's simply how COVID behaves. Once again, something we appreciate about our approach is that it generates those cross-reactive mucosal IgA responses, and our belief is that they will prove helpful over time as new variants emerge.

Liang Cheng

analyst
#23

And turning to the norovirus program as well. I'm just curious — what data did the FDA ask for? Could you share any detail on that?

Sean Tucker

executive
#24

Sure. At this point we aren't going to discuss particular asks or stipulations. What we're doing is evaluating the guidance that came our way, and we believe it gave us more clarity regarding what's needed to reach a productive end of Phase II meeting.

Ed Berg

executive
#25

Thanks. A few questions have come in from our retail investors, and I'll kick things off with one we touched on already—though I'd like Sean to expand on it a bit. How soon are you able to launch the phase of the trial involving 10,000 participants? And I believe part of that relates to timing, along with the FDA and DSMB review?

Sean Tucker

executive
#26

Right, so our aim as a business is to get the sentinel cohort signed up quickly, and I'd say that's moving along nicely. Like we've said before in earlier comments, we're looking for that to wrap up very shortly — in fact, within this month. Once enrollment is finished, and assuming the independent DSMB plus the FDA give a positive review of the 30-day safety data, what we intend to do is kick off enrollment right away for the trial's second phase, which at this point we expect to happen in early 2025.

Ed Berg

executive
#27

Appreciate it. One more inquiry regarding the study that came through: does the groundwork for getting that study underway involve bringing participants on board?

Sean Tucker

executive
#28

Absolutely. So, I want to start by acknowledging the tremendous effort put in by our committed team. We're fully ready to move forward with the second portion of the study, assuming we get a positive assessment of the 30-day safety data from the independent DSMB and from the FDA. We have strong confidence in our capacity to supply sites with both the investigational vaccine and the comparator, and we've collaborated very closely with our CRO to make sure sites are prepared; and naturally, we already have several sites up and running that have randomized participants for a sentinel cohort, plus many more sites that are set to take part in the upcoming phase.

Ed Berg

executive
#29

There's one additional question I wanted to raise. Regarding the norovirus program — you might have already addressed this completely, but I'll go ahead and ask anyway: when it comes to your work on norovirus, what would be the most sensible thing to do next?

Sean Tucker

executive
#30

Once more, what we're aiming for is an end of Phase II meeting with the FDA, where we'd talk through what Phase III and licensure require. That said, reaching that point means we have to bring additional data into our overall package. Our approach will stay thoughtful and deliberate as we go, and we'll make sure the data package we put together for the FDA is as compelling as it can be.

Ed Berg

executive
#31

Here's something I'd like to ask Steve. Would you be open to running a study in a country other than the U.S., possibly together with the partner?

Steve Lo

executive
#32

Absolutely. So we remain willing to work alongside other companies on joint development of our platform, as well as to pursue nondilutive funding possibilities with organizations based outside the U.S., whenever that makes solid commercial sense. Our vaccine work could therefore matter not just within the United States but globally as well. Broader partnerships are certainly something we welcome. To illustrate, as Sean noted before, we ran our Phase I norovirus study among breastfeeding mothers in South Africa, and the Bill & Melinda Gates Foundation provided the funding for it.

Ed Berg

executive
#33

Appreciate it. I’ve got one more question, and it’s directed at Sean. Are there any further developments you can share about the programs in their earlier stages, including seasonal flu, HPV, or avian flu? Should we expect any preclinical data? Also, is there one program that you’re putting at the front of the queue?

Sean Tucker

executive
#34

Right now, we have preclinical efforts underway for avian flu, seasonal flu, and HPV. When it comes to bird flu, data we generated previously indicated our platform could potentially work against multiple strains of that virus, though no studies have been run by us on the strains currently circulating — the ones present in the U.S. Also, as I noted earlier, we had a paper published in vaccines concerning our HPV constructs, and we routinely examine our candidate pipeline to figure out where the best strategic opportunities lie. Such decisions are made by the company on the basis of numerous factors, among them market and competitive dynamics, resources, and timing. Beyond these programs, we will keep carrying out preclinical development of novel constructs to brand both current and emerging infectious disease threats for pandemic preparedness.

Ed Berg

executive
#35

Appreciate it. That brings us to the end of the questions we have right now. I'll now hand things over to Steve Lo, who has a few closing comments.

Steve Lo

executive
#36

Absolutely. I appreciate all of you taking the time to be with us on this call today. Here at Vaxart, we're putting in tremendous effort as we aim to transform the way global public health is approached. Backing vaccine development represents not just a commitment to health, but also to the strength and thriving of our worldwide community; as trailblazers in oral vaccines, we take pride in bringing innovation to this field. Our distinctive strategy, which centers on mucosal immunity, is something we believe will prove essential to achieving our goals. That's why we remain hopeful about the bright future ahead of us, and we're eager to share news of our advancements with all of you. Operator, please go ahead and end the call.

Operator

operator
#37

Thanks. That wraps up the call for today, and you can go ahead and hang up whenever you're ready. We appreciate you joining us.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Vaxart, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Vaxart, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Vaxart, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.